RxDoctor Payments Data

Jose Angelo de Dios, MD

Pulmonary Disease · Norwich, CTNPI 1124227020

Payments from drug & device makers

$7,888in general payments, 2019–2025

Across 421 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$540
  • Mallinckrodt Hospital Products Inc.$471
  • Olympus Corporation Of The Americas$449
  • Jazz Pharmaceuticals Inc.$409
  • Boehringer Ingelheim$346
  • plus $3K from 36 others

What the payments were for

  • Travel & lodging$3955%
  • Food & beverage$7,25892%
  • Education$2353%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,888 in reported general payments places this provider in the 70th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$201,066
Medicare patients
567
Services billed
2,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter477$697,052
Dupixent PenDupilumab41$235,466
Breztri AerosphereBudesonide/Glycopyr/Formoterol97$128,813
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr78$94,589
Spiriva RespimatTiotropium Bromide64$76,173
Breo ElliptaFluticasone/Vilanterol107$71,181
Stiolto RespimatTiotropium Br/Olodaterol Hcl62$64,392
SymbicortBudesonide/Formoterol Fumarate39$21,298
Albuterol Sulfate HfaAlbuterol Sulfate459$17,291
Combivent RespimatIpratropium/Albuterol Sulfate12$16,686
Fluticasone-VilanterolFluticasone/Vilanterol17$10,990
DalirespRoflumilast17$10,167
Advair HfaFluticasone Propion/Salmeterol12$9,434
Ventolin HfaAlbuterol Sulfate79$8,356
Roflumilast60$7,706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,229$862,822662 claims
AstraZenecaBreztri Aerosphere, Symbicort, Daliresp$540$160,278153 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$346$157,251138 claims
MerckBelsomra$35$4,84311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →